IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility
Wang, Y.; Xu, L. P.; Liu, K. Y.; Liu, D. H.; Wang, J.; Chen, H.; Chen, Y. H.; Han, W.; Huang, X. J.
关键词acute GVHD MTX methylprednisolone
刊名BONE MARROW TRANSPLANTATION
2011-06-01
DOI10.1038/bmt.2010.197
46期:6页:892-898
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]VERSUS-HOST-DISEASE ; STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; GRAFT ; METHOTREXATE ; PREDNISONE ; TRIAL
英文摘要

To study the efficacy and safety of a low dose of MTX combined with a low dose of methylprednisolone (MP) as a first-line therapy in the treatment of acute GVHD (aGVHD) after allogeneic hematopoietic SCT, 32 patients received i.v. MTX at a dose of 10 mg or oral MTX at a dose of 15 mg every 3-7 days (repeated at day 3 after the first dose and then at a weekly interval) combined with a low dose of MP (0.5 mg/kg/day) until a complete or partial response was achieved, or until treatment failure or intolerable side effects occurred. The overall treatment response rate was 81% (26/32 patients) and the response rate at day 28 was 75% (24/32 patients). The response rate for GVHD involving various organs was 88% (23/26) in the skin, 75% (3/4) in the liver and 81% (9/11) in the gut. Grade 3 toxicities occurred in only three patients presenting cytopenias. The estimated survival at 2 years was 77%. From this analysis, MTX in combination with a low dose of MP appears to be a well-tolerated, effective and inexpensive regime when used as a first-line treatment for aGVHD. Bone Marrow Transplantation (2011) 46, 892-898; doi: 10.1038/bmt.2010.197; published online 16 August 2010

语种英语
WOS记录号WOS:000291383100019
项目编号30725038 ; IRT 0702
资助机构National Outstanding Young Scientist&prime ; s Foundation of China ; Program for Innovative Research Team in University ; Leading Program of Clinical Faculty
引用统计
被引频次:10[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60685
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Y.,Xu, L. P.,Liu, K. Y.,et al. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility[J]. BONE MARROW TRANSPLANTATION,2011,46(6):892-898.
APA Wang, Y..,Xu, L. P..,Liu, K. Y..,Liu, D. H..,Wang, J..,...&Huang, X. J..(2011).Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility.BONE MARROW TRANSPLANTATION,46(6),892-898.
MLA Wang, Y.,et al."Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility".BONE MARROW TRANSPLANTATION 46.6(2011):892-898.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Y.]的文章
[Xu, L. P.]的文章
[Liu, K. Y.]的文章
百度学术
百度学术中相似的文章
[Wang, Y.]的文章
[Xu, L. P.]的文章
[Liu, K. Y.]的文章
必应学术
必应学术中相似的文章
[Wang, Y.]的文章
[Xu, L. P.]的文章
[Liu, K. Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。